ClinicalTrialsFinder
RecruitingNCT03402919

Comprehensive Assessment of Neurodegeneration and Dementia

The Comprehensive Assessment of Neurodegeneration and Dementia Study

Sponsor

McGill University

Enrollment

1,573 participants

Start Date

Jun 1, 2016

Study Type

OBSERVATIONAL

Conditions

DementiaMild Cognitive Impairment (MCI)Subjective Cognitive ImpairmentLewy Body Disease(LBD)Alzheimer Disease (AD)Frontotemporal Dementia (FTD)Subjective Cognitive Decline (SCD)Mixed DementiaParkinson's Disease (PD)Cognitively Unimpaired

Summary

This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.

Eligibility

Min Age: 50 YearsMax Age: 90 Years

Inclusion Criteria7

  • Has subjective or objective cognitive impairment
  • Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member)
  • Sufficient proficiency in English or French to undertake self report and neuropsychological testing
  • Geographic accessibility to the study site
  • Must have a study partner who can participate as required in the protocol (provide corroborative information)
  • Up to 12 years of education
  • Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment

Exclusion Criteria4

  • The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses
  • Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures
  • Symptomatic stroke within the previous year
  • Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure

Locations(19)

University of Calgary

Calgary, Alberta, Canada

University of Alberta Hospital

Edmonton, Alberta, Canada

Djavad Mowafaghian Centre for Brain Health

Vancouver, British Columbia, Canada

Island Health

Victoria, British Columbia, Canada

Veteran's Memorial Building

Halifax, Nova Scotia, Canada

Hamilton General Hospital

Hamilton, Ontario, Canada

St. Joseph's Health Care London

London, Ontario, Canada

Gait and Brain Lab

London, Ontario, Canada

Bruyère Research Institute

Ottawa, Ontario, Canada

Kawartha Centre

Peterborough, Ontario, Canada

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

University Health Network Memory Clinic

Toronto, Ontario, Canada

Baycrest Clinical Unit

Toronto, Ontario, Canada

University of Waterloo

Waterloo, Ontario, Canada

Research Institute of the McGill University Health Centre

Montreal, Quebec, Canada

Jewish General Hospital/McGill Memory Clinic

Montreal, Quebec, Canada

Clinique de cognition Institut universitaire de gériatrie de Montréal

Montreal, Quebec, Canada

Hôpital Enfant-Jésus

Québec, Quebec, Canada

Centre de recherche sur le vieillissement CIUSSS de l'Estrie-CHUS

Sherbrooke, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03402919

Related Trials

A Study of Buntanetap in Participants With PD

NCT0728478426 locations

Lombard Cohort of Brain Health Services

NCT074571385 locations

Dementia Caregivers' Link to Assistance and Resources

NCT068600351 location

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789141 locations

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

NCT067809173 locations